Analysts Set Pfizer Inc. (NYSE:PFE) Price Target at $31.92

Pfizer Inc. (NYSE:PFE) has received a consensus rating of “Moderate Buy” from the sixteen analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $31.92.

A number of research firms have weighed in on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Guggenheim restated a “buy” rating and set a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th.

Pfizer Stock Performance

NYSE:PFE opened at $26.67 on Friday. The stock’s fifty day moving average is $26.33 and its 200 day moving average is $27.38. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The firm has a market capitalization of $151.14 billion, a PE ratio of 18.92, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm posted $0.10 earnings per share. The business’s revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.45%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.